Sartorius Stedim Biotech S.A. (ETR:56S1)

Market Cap	20.12B
Revenue (ttm)	2.95B
Net Income (ttm)	263.90M
Shares Out	n/a
EPS (ttm)	2.71
PE Ratio	76.25
Forward PE	40.86
Dividend	0.69 (0.34%)
Ex-Dividend Date	Apr 2, 2025

Volume	70
Average Volume	106
Open	n/a
Previous Close	203.70
Day's Range	n/a
52-Week Range	150.90 - 227.90
Beta	n/a
RSI	49.18
Earnings Date	Feb 3, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog...

• Industry: Laboratory Analytical Instruments
• Founded: 1978
• Employees: 9,901
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 56S1

Financial Performance

In 2024, Sartorius Stedim Biotech's revenue was 2.78 billion, an increase of 0.16% compared to the previous year's 2.78 billion. Earnings were 175.10 million, a decrease of -43.57%.